Clinical Trials

900 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT06991556 2026-04-16

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

150 enrolled

Metastatic Hormone-sensitive Prostate Cancer

NCT07226986 2026-04-16

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

123 enrolled

PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

NCT06136650 2026-04-15

MK-5684-004

1,314 enrolled

Prostatic Neoplasms

NCT06592924 2026-04-14

TRIPLE-SWITCH

830 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT02225704 2026-04-13

Radium-223 in Combination With Enzalutamide

Phase 2 Completed

45 enrolled

Prostatic Neoplasms

NCT02960022 2026-04-13

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

900 enrolled

Prostatic Neoplasms

NCT03869762 2026-04-13

DICE

Phase 2 Terminated

7 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT05818683 2026-04-13

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

300 enrolled

Metastatic Castration-resistant Prostate Neoplasms

NCT06616155 2026-04-13

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

39 enrolled

Prostatic Neoplasms

NCT06863272 2026-04-13

IDeate-Prostate02

360 enrolled

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT04787744 2026-04-08

VA STARPORT

Phase 2/3 Recruiting

464 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT06136624 2026-04-08

OMAHA-003

1,310 enrolled

Prostate Cancer Metastatic

NCT07287150 2026-04-08

InavoPC

100 enrolled

Phase 3 Active not recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

599 enrolled

Prostatic Neoplasms

NCT06632977 2026-04-07

PREDICT

474 enrolled

Prostatic Neoplasms

NCT04363164 2026-04-06

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

150 enrolled

Castration Resistant Metastatic Prostate Cancer

NCT06120491 2026-04-03

EvoPAR-PR01

1,800 enrolled

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06734130 2026-04-01

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

25 enrolled

Prostatic Neoplasms

NCT03674814 2026-03-31

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

Phase 1 Completed

42 enrolled

Prostatic Neoplasms

NCT04221542 2026-03-30

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

479 enrolled

Bites and Stings, Prostatic Neoplasms

NCT07028853 2026-03-30

MEVPRO-3

1,000 enrolled

Prostatic Neoplasms

NCT06096870 2026-03-25

Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

65 enrolled

Prostatic Neoplasms

NCT06457919 2026-03-24

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

50 enrolled

Prostatic Neoplasms

NCT05751941 2026-03-16

Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer

26 enrolled

Prostatic Neoplasms

NCT05526248 2026-03-11

ARAMON

Phase 2 Completed

28 enrolled 14 charts

Biochemically Recurrent Prostate Cancer

NCT04179864 2026-03-10

CELLO-1

Phase 1/2 Terminated

102 enrolled 39 charts

Prostatic Neoplasms

NCT06691984 2026-03-06

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

675 enrolled

Neoplasms, Prostatic Neoplasms

NCT05726292 2026-03-04

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

90 enrolled

Prostatic Neoplasms

NCT06551324 2026-03-04

MEVPRO-1

600 enrolled

Prostatic Neoplasms, Recurrence

NCT07230106 2026-03-03

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

218 enrolled

Prostatic Neoplasms

NCT05700903 2026-03-02

ARCH

Phase 4 Completed

10 enrolled

Phase 2 Active not recruiting

Hypertension, Kidney Diseases, Prostatic Neoplasms, Primary Dysautonomias

NCT03344211 2026-02-27

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

30 enrolled

Prostatic Neoplasms

NCT06257693 2026-02-27

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

56 enrolled

Prostate Adenocarcinoma

NCT01885949 2026-02-24

Tivozanib + Enzalutamide in Adv Prostate Cancer

Phase 2 Terminated

5 enrolled 7 charts

Phase 1/2 Active not recruiting

Neoplasm Metastasis, Prostatic Neoplasms

NCT02522715 2026-02-24

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

37 enrolled 10 charts

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT03016741 2026-02-24

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

100 enrolled

Dementia, Prostatic Neoplasms, Cognitive Dysfunction, Prostatic Neoplasms, Castration-Resistant

NCT05997615 2026-02-24

AMX-500

390 enrolled

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06855277 2026-02-24

AcTFirst

940 enrolled

Prostatic Neoplasms

NCT02861573 2026-02-17

KEYNOTE-365

1,200 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT06236139 2026-02-17

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

48 enrolled

Phase EARLY_PHASE1 Active not recruiting

Prostatic Neoplasms

NCT05683964 2026-02-13

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

9 enrolled